Anti-Tau Therapy Failure Mechanism in PSP — Why Clinical Trials Have Not Succeeded

Experiment Design: Anti-Tau Therapy Failure Mechanism in Progressive Supranuclear Palsy

Executive Summary

This experiment addresses the critical knowledge gap: "Why have anti-tau therapies failed in PSP despite strong biological rationale?" (Rank #10, PSP Knowledge Gaps). Multiple anti-tau antibody trials have failed in PSP, including gosuranemab (TANGOS) and tilavonemab, despite compelling preclinical data. This experiment will systematically investigate the mechanisms of these failures to inform next-generation therapeutic development.

Hypothesis

Experiment Design: Anti-Tau Therapy Failure Mechanism in Progressive Supranuclear Palsy

Executive Summary

This experiment addresses the critical knowledge gap: "Why have anti-tau therapies failed in PSP despite strong biological rationale?" (Rank #10, PSP Knowledge Gaps). Multiple anti-tau antibody trials have failed in PSP, including gosuranemab (TANGOS) and tilavonemab, despite compelling preclinical data. This experiment will systematically investigate the mechanisms of these failures to inform next-generation therapeutic development.

Hypothesis

Anti-tau antibody failures in PSP result from one or more of the following mechanisms:

Primary Objectives

Study Design

Phase 1: PSP Brain Tissue Analysis

Sample: Post-mortem brain tissue from 20 PSP patients (Richardson's syndrome, PSP-P variants) and 10 age-matched controls

Analyses:

• Sequential extraction (RIPA, formic acid) to separate soluble, membrane-bound, and insoluble tau fractions
• SDS-PAGE and western blot to characterize tau isoforms (4R vs. 3R/4R ratio)
• ELISA for specific tau fragments (N-terminal, mid-domain, C-terminal, phosphorylated at Ser202, Thr181, Ser396/404)
• immunohistochemistry for tau distribution (neuronal, oligodendroglial, extracellular)
• Electron microscopy for tau filament structure

Phase 2: Antibody Epitope Mapping

Antibodies to test:

• Gosuranemab (N-terminal anti-tau)
• Tilavonemab (mid-domain anti-tau)
• Semorinemab (central domain)
• E2814 (MTBR-domain, in clinical trials)
• Posdinemab (phospho-tau specific)

• Dot blot with synthetic tau peptides spanning full-length tau
• Surface plasmon resonance (SPR) for binding kinetics
• Cryo-EM to visualize antibody-FAB binding to PSP-derived tau filaments
• Competition assays to determine epitope overlap

Phase 3: Ex Vivo Antibody Engagement

Method:

• Incubate fresh frozen PSP brain sections with each antibody
• Image using confocal microscopy to quantify antibody penetration and binding
• Compare to antibody binding in AD brain (where antibodies have shown efficacy)
• Test whether adding permeabilization or enzymatic treatment improves binding

Phase 4: Biomarker Development

Samples: CSF and plasma from 100 PSP patients, 50 PD patients, 50 controls

Biomarkers to measure:

• Total tau, p-tau181, p-tau217, p-tau205
• NfL, GFAP
• Tau种子 (RT-QuIC or PMCA)
• Tau proteoforms (capillary electrophoresis)

• Clinical severity (PSPRS, MoCA)
• Disease duration
• MRI atrophy patterns

Model Systems

In Vitro Models

• iPSC-derived neurons from PSP patients (MAPT mutations P301S, S305I)
• iPSC-derived oligodendrocytes (relevant for coiled body pathology)
• Organoid models with 4R-tau pathology

Animal Models

• PS19 mice (P301S tau) — test antibody efficacy
• AAV-mediated 4R-tau overexpression in mice — test timing effects
• Non-human primates for translational studies

Expected Outcomes

Feasibility Assessment

| Dimension | Score | Rationale |
|-----------|-------|-----------|
| Mechanistic Impact | 10 | Will directly explain why billions invested in anti-tau trials failed |
| Cure Proximity | 9 | Enables rational next-generation trial design |
| Feasibility | 7 | Requires PSP brain tissue, which is available through brain banks |
| Cost Efficiency | 8 | Leverages existing failed trial materials and data |
| Timeline | 8 | Can begin within 6 months; 24-month primary analysis |
| Cross-Disease Value | 9 | Findings apply to CBD, AD, and other tauopathies |
| Biomarker Enablement | 10 | Directly enables biomarker-driven trial design |
| Combinability | 8 | Compounds with other experiments (tau spreading, oligodendrocyte function) |
| De-risking Value | 10 | Critical for avoiding another failed $500M Phase 3 trial |
| Novelty | 9 | First systematic analysis of anti-tau failure mechanisms |

Total Score: 78/100

Budget Estimate

| Component | Cost |
|-----------|------|
| Brain tissue acquisition (20 PSP, 10 control) | $50,000 |
| Biochemical analyses | $80,000 |
| Antibody testing and epitope mapping | $60,000 |
| Cryo-EM | $100,000 |
| Biomarker development (100 pts) | $70,000 |
| iPSC differentiation | $40,000 |
| Personnel (2 FTE × 2 years) | $200,000 |
| Total | $600,000 |

Timeline

| Milestone | Timepoint |
|-----------|-----------|
| Brain tissue acquired | Month 6 |
| Phase 1 complete (tau species catalog) | Month 12 |
| Phase 2 complete (epitope mapping) | Month 18 |
| Phase 3 complete (ex vivo engagement) | Month 24 |
| Phase 4 complete (biomarker panel) | Month 30 |
| Final analysis and publication | Month 36 |

Risk Mitigation

| Risk | Mitigation |
|------|------------|
| Limited PSP brain tissue availability | Partner with multiple brain banks (Mayo, UCSF, Cambridge) |
| Antibody manufacturers unwilling to share | Use publicly available data; test biosimilars |
| Findings too late for current trials | Publish interim results; engage pharma partners early |

References

Related Pages

• [Experiment Priority Index](/experiments/experiment-priority-index)
• [4R-Tau Targeting in PSP/CBS](/experiments/4r-tau-targeting-psp-cbs)
• [Tau Spreading Network Mapping in PSP](/experiments/tau-spreading-network-mapping-psp)
• [PSP Knowledge Gaps](/gaps/progressive-supranuclear-palsy)
• [CBS/PSP Cure Roadmap](/mechanisms/cbs-psp-cure-roadmap)

Pathway Diagram

The following diagram shows the key molecular relationships involving Anti-Tau Therapy Failure Mechanism in PSP — Why Clinical Trials Have Not Succeeded discovered through SciDEX knowledge graph analysis: